GeneDx Secures $100M Term Loan from Blackstone, Refinancing Existing Debt and Boosting Liquidity

summarizeSummary

GeneDx secured a $100 million term loan from Blackstone, refinancing existing debt and providing capital for balance sheet optimization and general corporate purposes.

check_boxKey Events

• New $100 Million Term Loan Secured

  GeneDx entered into a Loan Agreement with Blackstone for a $100.0 million term loan, funded on February 27, 2026.

• Debt Refinancing and Balance Sheet Optimization

  Proceeds from the new loan were used to repay the existing credit agreement and are earmarked for balance sheet optimization initiatives and general corporate purposes.

• Five-Year Maturity and Security

  The Term Loan matures in five years, bears interest at Term SOFR + 4.50% (with a 1.50% SOFR floor), and is secured by a first lien on substantially all company assets.

• Minimum Liquidity Covenant

  The Loan Agreement includes a minimum liquidity covenant requiring the company to maintain at least $50 million in liquidity.

auto_awesomeAnalysis

GeneDx Holdings Corp. has secured a significant $100 million term loan from Blackstone, which will be used to repay its existing credit facility and for general corporate purposes, including balance sheet optimization. This new financing provides substantial liquidity and operational flexibility, reinforcing the company's financial stability following its recent report of strong 2025 financial results and positive operating cash flow. The five-year term loan, secured by company assets, demonstrates continued access to capital and supports ongoing strategic initiatives, particularly important given the previously disclosed material weakness.